

1 Nitric oxide production and sequestration in the sinus gland of the green shore crab,
2 *Carcinus maenas*

3
4 Natalie L. Pitts and Donald L. Mykles*

5
6 *Department of Biology, Colorado State University, Fort Collins, CO 80523 USA*
7
8

9 Running title: Nitric oxide production in the sinus gland

10
11 Key words: nitric oxide, nitric oxide synthase, sinus gland, eyestalk ganglia, copper fluorescent
12 ligand, confocal microscopy, tissue distribution, protein expression, Brachyura, Crustacea,
13 Arthropoda
14
15
16
17
18
19

20 *Corresponding author:

21 Dr. Donald L. Mykles
22 Department of Biology
23 Colorado State University
24 Campus Delivery 1878
25 Fort Collins, CO 80523 USA
26 Office: 970-491-7616
27 Fax: 970-491-0649
28 E-mail: Donald.Mykles@ColoState.edu
29

30 Abstract

31 Molting in decapod crustaceans is regulated by molt-inhibiting hormone (MIH), a
32 neuropeptide produced in the X-organ (XO)/sinus gland (SG) complex of the eyestalk ganglia
33 (ESG). Pulsatile release of MIH from the SG suppresses ecdysteroidogenesis by the molting
34 gland or Y-organ (YO). The hypothesis is that nitric oxide (NO), a neuromodulator that controls
35 neurotransmitter release at presynaptic membranes, depresses the frequency and/or amount of
36 MIH pulses to induce molting. NO synthase (NOS) mRNA was present in *Carcinus maneus*
37 ESG and other tissues and NOS protein was present in the SG. A copper based ligand (CuFL),
38 which reacts with NO to form a highly fluorescent product (NO-FL), was used to image NO in
39 the ESG and SG and quantify the effects of NO scavenger (cPTIO), NOS inhibitor (L-NAME),
40 and sodium azide (NaN_3) on NO production in the SG. Preincubation with cPTIO prior to CuFL
41 loading decreased NO-FL fluorescence ~30%; including L-NAME had no additional effect.
42 Incubating SG with L-NAME during preincubation and loading decreased NO-FL fluorescence
43 ~40%, indicating that over half of the NO release was not directly dependent on NOS activity.
44 Azide, which reacts with NO-binding metal groups in proteins, reduced NO-FL fluorescence to
45 near background levels without extensive cell death. Spectral shift analysis showed that azide
46 displaced NO from a soluble protein in SG extract. These data suggest that the SG contains NO-
47 binding protein(s) that sequester NO and releases it over a prolonged period. This NO release
48 may modulate neuropeptide secretion from the axon termini in the SG.

49 **Introduction**

50 Nitric oxide (NO) is a signaling molecule that is evolutionarily and functionally conserved
51 across animal taxa (Palumbo, 2005). NO is produced by nitric oxide synthase (NOS) from L-
52 arginine, O₂, and NADPH (Colasanti and Venturini, 1998). Three NOS isoforms occur in
53 mammalian cells: endothelial (eNOS), neuronal NOS (nNOS), and inducible NOS (iNOS)
54 (Nathan and Xie, 1994; Bogdan, 2001; Mungrue et al., 2003). eNOS and nNOS are
55 constitutively expressed and require Ca²⁺ and calmodulin for activation (Roman et al., 2002).
56 iNOS is a Ca²⁺ independent isoform that is up regulated during immunological responses
57 (Colasanti and Venturini, 1998). Decapod crustacean tissues express a single NOS that resembles
58 the Ca²⁺/calmodulin-dependent isoforms in functional domains and biochemical properties
59 (Johansson and Carlberg, 1994; Lee et al., 2000; Scholz et al., 2002; Zou et al., 2002; Kim et al.,
60 2004; McDonald et al., 2011). The crustacean NOS gene is expressed in many tissues, which is
61 consistent with its role as a regulator of diverse physiological functions (Lee et al., 2000; Kim et
62 al., 2004; Inada et al., 2010; Yao et al., 2010; McDonald et al., 2011; Li et al., 2012; Wu et al.,
63 2013).

64 In the central nervous systems (CNS) of vertebrates and invertebrates, NO functions as a
65 neuromodulator. In vertebrates, NO regulates learning, memory, feeding, sleeping, sensory, and
66 motor functions by acting as an inhibitor or enhancer of neurotransmitter release (Calabrese et
67 al., 2007; Garthwaite, 2008; Virarkar et al., 2013). For example, NO enhances acetylcholine
68 release in the basal forebrain and ventral striatum and inhibits histamine release in the anterior
69 hypothalamus (Philippu and Prast, 2001). In the vertebrate hippocampus and cerebral cortex, NO
70 plays a dual role in the regulation of glutamate release, acting as an inhibitor at low
71 concentrations and a stimulator at high concentrations (Sequeira et al., 1997). In addition, NO
72 has neurotoxic effects that are associated with neurodegenerative disorders, such as Alzheimer's,
73 Parkinson's, and Huntington's diseases (Calabrese et al., 2007; Lorenc-Koci and Czarnecka,
74 2013; Virarkar et al., 2013; see Hirst and Robson, 2011 and Russwurm et al., 2013 for
75 comprehensive reviews of NO actions in vertebrates). In decapod crustaceans, NO acts as an
76 enhancer or inhibitor by increasing neurotransmitter release in the stomatogastric ganglion and
77 depressing release in neuromuscular junctions, respectively (Scholz, 1999; Aonuma et al., 2000,
78 2002).

79 NO signaling regulates molting and developmental timing in arthropods. In insects,
80 prothoracicotrophic hormone (PTTH)-induced stimulation of the molting gland (prothoracic gland
81 or PG) requires NOS activation (Caceres et al., 2011; Rewitz et al., 2013). In the molting gland
82 or Y-organ (YO) of the blackback land crab *Gecarcinus lateralis*, NO donors and YC-1, an
83 agonist of NO-dependent guanylyl cyclase (GC-I), inhibit ecdysteroidogenesis in YO and NOS
84 becomes phosphorylated in the activated YO, which suggests that NOS and GC-I are
85 components of a signaling pathway activated by molt-inhibiting hormone [MIH (Mykles et al.,
86 2010; Chang and Mykles, 2011; Covi et al., 2012)]. MIH is a neuropeptide that represses the YO
87 to maintain the animal in the intermolt stage; a reduction in MIH release is believed to result in
88 the de-repression of steroidogenesis by the YO (Skinner, 1985; Lachaise et al., 1993; Chang and
89 Mykles, 2011). MIH is synthesized in the X-organ (XO), which consists of a cluster of ~150
90 neurosecretory cells located in the medulla terminalis (MT) of the eyestalk ganglia (Skinner,
91 1985; Hopkins, 2012). Axons from the XO terminate in the sinus gland (SG), a neurohemal
92 organ where MIH and other XO neuropeptides are released into the hemolymph (Skinner, 1985;
93 Stuenkel, 1985; Hopkins, 2012). The SG consists of glial cells, axons, and axon terminals
94 (Azzouna and Rezig, 2001). NOS protein is localized to the SG of the crayfish, *Procambarus*
95 *clarkii*, which is suggestive of a role in neuroendocrine regulation (Lee et al., 2000).

96 The regulation of neuropeptide synthesis and release by the XO/SG complex is poorly
97 understood. mRNA levels of MIH and crustacean hyperglycemic hormone (CHH) in the ESG
98 remain unchanged throughout the molt cycle in *Carcinus maenas*, indicating that MIH and CHH
99 are regulated post-transcriptionally [(Chung and Webster, 2003); N. L. Pitts and D. L. Mykles,
100 unpublished]. The MIH neurons in the XO/SG complex are under serotonergic control (Rudolph
101 and Spaziani, 1991) and neuropeptide release is triggered by entry of Ca^{2+} (Cooke, 1985). The
102 purpose of this study was to examine the potential role of NO signaling in the XO/SG complex
103 of the green shore crab, *C. maenas*. Endpoint RT-PCR was used to determine the expression of
104 *Cm-NOS* and *Cm-Elongation Factor-2 (EF2)* in the eyestalk ganglia and other tissues. The
105 presence of NOS protein in the SG was determined by Western blot analysis. CuFL, a copper (II)
106 fluorescein-based ligand (Lim et al., 2006), was used to localize NO and quantify the effects of
107 NOS inhibitor (L-NAME), NO scavenger (cPTIO), or both compounds on NO production in the
108 SG. The effect of sodium azide (NaN_3), which reacts with heme and other metal groups, on NO-
109 FL fluorescence was quantified. An azide-dependent spectral shift analysis characterized NO-

110 binding protein(s) in SG soluble extract. The results indicate that NO produced by NOS binds to
111 an endogenous store, allowing for prolonged release of the gas to the axon terminals of the SG.
112 To our knowledge, this is the first study using CuFL to quantify and image NO in crustacean
113 tissues and to characterize NO-binding protein(s) in the SG.

114

115 **Results**

116 *Tissue expression of Cm-NOS*

117 The tissue distribution of *Cm-NOS* was assessed by end point PCR in tissues from a single
118 red color morph intermolt male. *Cm-NOS* mRNA was detected in all tissues examined, except
119 the heart and hepatopancreas (Fig. 1). *Cm-EF2* was expressed in all tissues (Fig. 1).

120

121 *Detection of NOS protein by Western blotting*

122 NOS protein was present in the SG, as shown by Western blotting with a universal NOS
123 antibody (Fig. 2). An immunoreactive protein of the predicted molecular weight (~132 kDa) was
124 detected with the primary antibody (Fig. 2, lane a). A second protein with an estimated mass of
125 94 kDa may represent a truncated NOS isoform (see Discussion). Based on scanning
126 densitometry, the level of the ~94-kDa protein was about 2-fold greater than the level of the
127 ~132-kDa protein.

128

129 *Imaging and quantification of NO-FL fluorescence*

130 NO was quantified with CuFL. NO reacts with CuFL to form NO-FL, a highly fluorescent
131 product that becomes trapped in the cells (Lim et al., 2006). The CuFL concentration used in the
132 experiments was optimized by loading SG with 10-fold serial dilutions between 0.5 mM and
133 0.05 μ M CuFL in the presence or absence of the NO scavenger cPTIO or the NOS inhibitor L-
134 NAME. Loading time was 1 h. NO-FL was highly fluorescent at higher concentrations (> 5 μ M),
135 which saturated the tissue and obscured imaging tissue structure with confocal microscopy. A
136 concentration of 0.05 μ M was selected, as at that concentration background fluorescence was
137 minimized, while the effects of cPTIO and/or L-NAME on fluorescent intensity could be
138 quantified with Metamorph imaging software.

139

140 SG *in situ*. ESG was preincubated in crab saline for 30 min and then loaded with 0.05 μ M CuFL

141 for 1 h in the dark. NO-FL fluorescence intensity was greater in the SG compared to the
142 surrounding medulla interna [MI (Fig. 3, left panel)]. In bright field images, the SG appeared
143 dark due to the accumulation of neuropeptide secretory vesicles in axon termini (Fig. 3, middle
144 panel). NO-FL fluorescence in the isolated SG was comparable to that of the *in situ* SG (see Fig.
145 4B), indicating that the fluorescence in the isolated SG was not an artifact of dissection. The
146 pattern of NO-FL fluorescence indicated that NO was produced in glial and other supporting
147 cells and not in axon termini.

148 The effects of reagents on NO-FL fluorescence were determined on the isolated SG. Initial
149 experiments examined the effects of pretreatment conditions and also confirmed that NO was
150 produced in the SG. Although the relative NO-FL fluorescence varied between individuals, there
151 was no difference in fluorescence between the two SG from the same individual (data not
152 shown). SG were preincubated in the dark for 30 min in crab saline, 1 mM cPTIO, or 1 mM
153 cPTIO + 1 mM L-NAME, followed by loading for 1 h in the dark with or without 0.05 μ M
154 CuFL. SG loaded without CuFL had less than 5% of the fluorescence ($p = 0.002$) compared to
155 SG loaded with CuFL after preincubation in crab saline, showing that the fluorescence was
156 specific for NO-FL and not due to tissue autofluorescence (Fig. 4A). Representative confocal
157 images show the absence of fluorescence in a SG without CuFL (Fig. 4B, panel 1), compared
158 with high fluorescence in a SG with CuFL (Fig. 4B, panel 2). Preincubation with cPTIO alone or
159 in combination with L-NAME reduced NO-FL fluorescence 35% and 26%, respectively,
160 compared to the saline pretreatment control (Fig. 4A). Corresponding confocal images showed a
161 general overall reduction in fluorescence in SG preincubated with cPTIO or with cPTIO + L-
162 NAME (Fig. 4B, compare panels 3 & 4 with panel 2). The reduction in fluorescence appeared to
163 be solely the result of cPTIO, as the addition of L-NAME during preincubation did not decrease
164 fluorescence further. This unexpected result suggested that there was significant NO production
165 and/or release during the 1-h loading period. These results showed that the NO concentrations in
166 the SG were within the linear response range at the concentration of CuFL used, and that CuFL
167 was a highly sensitive and specific reagent for localizing and quantifying NO in crustacean
168 tissues.

169 A second set of experiments examined the effects of cPTIO and L-NAME when in direct
170 competition with CuFL during the loading period. The experiments followed a similar protocol:
171 isolated SG were preincubated in the dark for 30 min in crab saline, 1 mM cPTIO and/or 1 mM

172 L-NAME, followed by loading for 1 h in the dark with 0.05 μ M CuFL in crab saline with or
173 without 1 mM cPTIO or 1 mM L-NAME. SG preincubated in saline and then incubated with
174 cPTIO and CuFL during loading had a 23% increase ($p = 0.047$) in fluorescence intensity than
175 the control SG without cPTIO (Fig. 5A). A similar trend was also observed when SG were
176 preincubated with cPTIO, but the difference was not significant (Fig. 5A). This suggested that
177 CuFL had a higher NO binding affinity and thus was a better scavenger of free NO than cPTIO.
178 This is particularly striking, considering the 20,000-fold difference in concentration between
179 cPTIO (1 mM) and CuFL (0.05 μ M). As shown in the first set of experiments, the NO-FL
180 fluorescence was similar in SG preincubated with cPTIO alone and SG preincubated with cPTIO
181 + L-NAME (Fig. 5A, compare columns #2 and #3). Representative confocal images showed
182 similar reductions in NO-FL fluorescence (Fig. 5B, compare panels #2 and #3 with panel #1).
183 Preincubation with cPTIO and L-NAME followed by L-NAME during the CuFL loading period
184 decreased NO-FL fluorescence 40% ($p < 0.001$) compared to the fluorescence without L-NAME
185 in the loading solution (Fig. 5A and 5B, compare panel #4 with panel #3). However, the
186 fluorescence in the continuous presence of L-NAME in the preincubation and loading periods
187 was well above the baseline level (Fig. 5A and Fig. 5B, panel #4), which suggested that more
188 than half of NO-FL fluorescence was not directly dependent on NOS activity.

189

190 *Effects of azide on NO-FL fluorescence and spectral shift analysis*

191 The failure of an NOS inhibitor and an NO scavenger to completely knock down NO-FL
192 fluorescence suggested that a proportion of the NO was bound by an endogenous protein(s), thus
193 preventing its rapid degradation. A variety of metalloproteins, including heme- and copper-
194 centered proteins, bind NO (Cooper, 1999; Wilson and Torres, 2004). During loading, the CuFL
195 would react with the NO as it was released from the metal group(s). In order to test this
196 hypothesis, SG were preincubated with 1 mM NaN_3 ; azide binds nearly irreversibly with metal
197 groups and dislodges bound gases, such as O_2 , CO_2 , H_2S , and NO (Martin et al., 1990). NaN_3
198 was restricted to the preincubation period, as it would react with CuFL during the loading period
199 and quench fluorescence. Isolated SGs were preincubated in saline containing cPTIO and L-
200 NAME with and without NaN_3 , followed by L-NAME during the loading period to minimize *de*
201 *novo* NO production by NOS. NaN_3 reduced NO-FL fluorescence 57% ($p = 0.033$) compared to
202 the control without NaN_3 (Fig. 5A; compare columns #4 and #5). This reduction was in addition

203 to the decreased NO-FL fluorescence with L-NAME, resulting in a fluorescent intensity
204 approaching that without CuFL (Fig. 4A, column #1). A representative confocal image shows
205 low NO-FL fluorescence, comparable to the images of SG not loaded with CuFL (compare Fig.
206 5B, panel #5, with Fig. 4B, panel #1). These data suggest that an endogenous protein(s) binds
207 NO, which was dissociated from the protein with azide.

208 The reduction of NO-FL fluorescence by azide was not associated with massive cell death.
209 Azide disrupts aerobic respiration; the reduced ATP production could affect cell viability. Thus,
210 the decrease in NO-FL fluorescence could be caused by the loss of NO-FL from dead cells and
211 not from the release of NO from an endogenous store. A cell viability stain was used to image
212 live and dead cells in SG incubated in crab saline (negative control), 1 mM NaN₃, or 70%
213 methanol (positive control) for 30 min. The SG was stained with propidium iodide (PI), which
214 preferentially stained nuclei of dead cells, followed by Hoechst stain, which stained nuclei of all
215 cells. In false-color images with PI in green and Hoechst in red, the nuclei of dead cells appeared
216 orange to yellow when the images were overlaid (Fig. 6). The numbers of dead and live cells
217 were counted by seven naïve observers and the dead:live ratio was calculated for each treatment.
218 All seven observers counted cells from the same images. There was no significance difference in
219 the ratios between observers ($p = 0.666$). The SG incubated in crab saline had the lowest number
220 of dead cells, with a 1.44 ± 0.42 dead:live ratio (Fig. 6, left panels). By contrast, in the SG
221 incubated in 70% methanol (MeOH), the PI and Hoechst staining almost completely overlapped,
222 resulting in an 11.38 ± 1.83 dead:live cell ratio; this is equivalent to 89% of all nuclei stained
223 with PI and Hoechst (Fig. 6, right panels). Azide increased the dead:live cell ratio to 2.66 ± 0.73
224 (Fig. 6, central panels). The dead:live cell ratio was significantly different among all three
225 treatments: control *vs.* azide ($p = 0.038$), control *vs.* MeOH ($p < 0.001$), and azide *vs.* MeOH ($p =$
226 0.002).

227 In order to characterize the NO binding protein(s), a spectral shift analysis was conducted
228 on SG soluble extract. Spectra from 190 nm to 1100 nm at 1-nm resolution were recorded of SG
229 extract prior to and immediately after the addition of 1 mM NaN₃ (Fig. 7; top panel), and at 5-
230 min intervals following the addition of NaN₃ over 1 h (Fig. 7; bottom panel). Differences in
231 spectral peaks were calculated by subtracting the spectra at each 5 min time interval from the
232 spectrum prior to the addition of NaN₃. No spectral shifts were observed in the ranges expected
233 for heme binding (400 nm - 450 nm) or copper binding (600 nm - 700 nm) proteins. In the long

234 UV range (210 to 450 nm), there was an increase in absorption centered broadly at ~234 nm and
235 a reduction in absorption centered broadly at ~272 nm, relative to the untreated sample (Fig. 7).
236 The absorption changes in these specific regions were completed within the first 5 minutes after
237 the addition of NaN₃, although there was a general drift in absorption as the protein precipitated
238 from solution.

239

240 Discussion

241 NO is an important signaling molecule that mediates numerous physiological processes,
242 such as neuromodulation, endocrine regulation, olfaction, and muscle contraction/relaxation
243 (Radomski et al., 1991; Martinez et al., 1994; Hurst et al., 1999; Bishop and Brandhorst, 2001).
244 The distribution of NOS in nervous and other tissues is consistent with diverse roles of NO in
245 decapod crustaceans [Fig. 1; (Kim et al., 2004; McDonald et al., 2011)]. The *C. maenas* SG
246 expressed a full-length NOS protein with a mass predicted from the cDNA sequence [~132 kDa;
247 Fig. 2 (McDonald et al., 2011)]. The observed ~94-kDa protein on the Western blot may
248 represent an uncharacterized truncated NOS isoform in the SG of *C. maenas* (Fig. 2). In
249 *Drosophila melanogaster*, for example, NOS isoforms ranging in mass between 22 kDa and 151
250 kDa are generated by alternative splicing and alternative start sites and some truncated isoforms
251 act as dominant negative regulators (Regulski and Tully, 1995; Stasiv et al., 2001). In
252 arthropods, NO production has largely been inferred from NOS localization using
253 immunohistochemistry or NADPH diaphorase histochemistry on fixed tissues (Scholz et al.,
254 1998; Scholz et al., 2002; Zou et al., 2002; Kim et al., 2004; Mahadevan et al., 2004; Yeh et al.,
255 2006; Ott et al., 2007; McDonald et al., 2011). 4,5-Diaminofluorescein-2 (DAF-2) was used to
256 detect NO in the terminal abdominal ganglion of the crayfish, *Pacifastacus leniusculus* and
257 hemocytes in the tiger shrimp, *Penaeus monodon* (Schuppe et al., 2002; Wu et al., 2013). The
258 present study used CuFL to localize and quantify NO production in the eyestalk ganglia and SG.
259 The major findings are: (1) CuFL is a highly specific and sensitive probe for NO in crustacean
260 tissue; (2) NO production in the *C. maenas* SG requires NOS activity; and (3) endogenous
261 protein(s) sequesters NO and releases NO over a prolonged period.

262 CuFL is a highly specific cell-permeable probe for NO in living cells (Lim et al., 2006;
263 McQuade et al., 2010; Gusarov et al., 2013). In order to establish that the fluorescence observed
264 after CuFL loading was NO-dependent, NOS inhibitor (L-NAME) and NO scavenger (cPTIO)

265 were used to reduce NO-FL fluorescence in the SG. Preincubation with cPTIO or cPTIO + L-
266 NAME decreased NO-FL fluorescence by ~30% (Fig. 4). Including L-NAME during CuFL
267 loading decreased fluorescence by 40% (Fig. 5), indicating that more than half of the NO-FL
268 fluorescence was not directly dependent on NOS activity. As NO has a half-life on the order of
269 seconds in aerated aqueous solutions (Moncada et al., 1991), the gas was apparently bound by an
270 endogenous protein, which released NO over the 1 h loading period. In the salivary glands of
271 several blood sucking insects, such as *Rhodnius prolixus* (Ribeiro et al., 1993), *Cimex lectularius*
272 (Weichsel et al., 2005), and *Triatoma infestans* (Assumpcao et al., 2008), NO is sequestered by
273 heme proteins. NO is reversibly bound to an Fe(III) heme protein that releases NO when exposed
274 to a neutral pH at the site of the wound. We hypothesized that NO was sequestered in a similar
275 manner in the SG of *C. maenas*. In order to test this hypothesis, 1 mM NaN₃ was added during
276 preincubation to drive the dissociation of NO from a protein to which it was bound. This resulted
277 in a further 57% reduction in fluorescence compared to SGs preincubated with cPTIO + L-
278 NAME without NaN₃ (Fig. 5), supporting the hypothesis that NO was bound by an endogenous
279 protein. To determine that the large reduction in NO-FL fluorescence by NaN₃ was not the result
280 of large-scale cell death, we used a propidium iodide cell viability stain to quantify the dead:live
281 cell ratio in SG incubated in saline, 1 mM NaN₃ in saline, or 70% MeOH for 30 min. SG treated
282 with azide had a 1.8-fold increase in dead cells compared to SG treated with crab saline (Fig. 6).
283 This compares with a 7.2-fold difference in NO-FL fluorescence between SG incubated with or
284 without azide (Fig. 5A, compare column #1 to #5). Thus, the increased cell death with azide
285 accounts for no more than 13% of the decrease in NO-FL fluorescence with azide.

286 To further characterize this protein, a spectral shift analysis was performed on a soluble
287 extract of isolated SGs in the presence of NaN₃. An azide-dependent dissociation of NO from a
288 heme group would cause a negative spectral shift in the Soret peak [400 nm- 450 nm; see
289 (Ribeiro et al., 1993)]. No spectral shift was observed in this range, indicating the NO-binding
290 moiety was not a heme group (Fig. 7). Alternatively, if an NO bound to a copper-containing
291 protein is displaced by NaN₃, we would expect a negative spectral shift in the 600 nm – 700 nm
292 range (Wilson and Torres, 2004). By contrast, azide caused a positive spectral shift in the 225
293 nm – 245 nm range and a negative shift in the 245 nm – 290 nm range. Further analysis is
294 needed to identify the NO-binding protein(s) involved. Nevertheless, the spectral shift analysis
295 showed that the SG contains an endogenous NO storage protein, but the moiety that bound NO

296 was not a heme or copper group. Absorption at ~272 nm is typical of phenylalanine, tyrosine,
297 and tryptophan side chains, which may suggest the formation of azidoadducts of aromatic amino
298 acids. p-Azidophenylalanine adducts of dihydrofolate reductase show an increased absorption at
299 ~250 nm (Carrico, 2004) compared to the unmodified enzyme, while 6-azidotryptophan shows
300 an absorption at 248 nm that is not present in unmodified tryptophan (Miles and Phillips, 1985).
301 The data indicate that azide displaces NO from a metal-containing protein(s), which is associated
302 with the reaction of azide with aromatic side chains.

303 CuFL was a better scavenger of NO than cPTIO. When cPTIO and CuFL were in direct
304 competition during the loading period, there was no decrease in NO-FL fluorescence in the SG
305 by cPTIO. Surprisingly, the fluorescent intensity was increased moderately (Fig. 5A), compared
306 to loading with CuFL alone. The concentration of cPTIO was 20,000 times greater than CuFL (1
307 mM vs. 0.5 μ M, respectively), suggesting that the increase in fluorescence observed when cPTIO
308 and CuFL were loaded together was a result of the CuFL being a more efficient NO scavenger
309 than cPTIO. This is consistent with results from experiments that included cPTIO during
310 preincubation and loading. cPTIO alone during preincubation could effectively scavenge NO and
311 reduce NO-FL fluorescence (Fig. 4). However, when CuFL was added to the cPTIO solution
312 during loading, fluorescence increased or did not change (Fig. 5), indicating that CuFL
313 outcompeted cPTIO for binding to free NO. Similar results were found when DAF-2 was used to
314 quantify NO in plant tissues; at high NO levels cPTIO increased DAF-2 NO fluorescence
315 (Vitecek et al., 2008). This effect was attributed to DAF-2 binding to N_2O_3 , a byproduct of the
316 reaction of cPTIO and NO. However, CuFL does not react with N_2O_3 . An alternative explanation
317 is that cPTIO reacts with cellular substrates, such as reductases, which prevents it from
318 scavenging NO (Haseloff et al., 1997). The high affinity of CuFL for NO makes it an excellent
319 NO probe for use in living tissues, even in the presence of NO scavengers.

320 Figure 8 is a schematic diagram that summarizes the reactions and the effects of reagents
321 during the preincubation and loading conditions. It is assumed that all the NO in the SG is
322 produced by NOS. Some of the NO binds reversibly to endogenous protein (XX-NO), while
323 some binds reversibly to GC-I and other NO-dependent enzymes (not included in the diagram).
324 cPTIO acts as an NO scavenger by converting NO to NO_2 , which can react with NO to form
325 N_2O_3 . CuFL reacts with NO to form NO-FL and Cu(I). As CuFL has a higher affinity for NO
326 than cPTIO, the formation of NO-FL is favored over the formation of NO_2 when both reagents

327 are present during loading. Azide reacts with the protein (N_3XX) and the released NO reacts with
328 water to form nitrite and nitrate. As preincubation with cPTIO or with cPTIO + L-NAME does
329 not affect NO release from endogenous proteins during CuFL loading, NO-FL fluorescence is
330 reduced but not completely eliminated. The largest reduction in NO-FL fluorescence is achieved
331 when the SG is preincubated with NaN_3 , cPTIO, and L-NAME. NaN_3 drives the release of NO
332 from endogenous stores and the NO reacts with cPTIO. L-NAME inhibits NOS and prevents NO
333 production during the preincubation period, as well as during the CuFL loading period.

334 Confocal microscopy revealed that NO-FL distribution was not uniform. Images of the SG
335 *in situ* (Fig. 3), as well as of the isolated SG (Figs. 4, 5), showed that NO-FL fluorescence was
336 preferentially located in cells that surrounded and penetrated the SG. The variation in NO-FL
337 fluorescence was not due to variations in the size and thickness of the tissue. As areas of strong
338 fluorescence occurred throughout the optical sections of the z-stack, the 1 h loading period was
339 sufficient time for the CuFL to penetrate to the interior of the SG. The SG is structured as a
340 network of groups swollen axon termini separated by glial cell projections (Fu et al., 2005). This
341 is apparent in the cell viability images, in which the nuclei of glial and other supporting cells
342 surround axon termini that lack nuclei (Fig. 6). The distribution of NO-FL is consistent with the
343 production of NO by supportive tissues containing glial cells (Figs. 3, 4B, and 5B). We conclude
344 that the site of NO production, storage, and release is confined to supportive structures and areas
345 within the SG lacking NO-FL fluorescence are axon termini. Additionally, several terminal types
346 are present in the SG (Fu et al., 2005), therefore areas of NO-FL fluorescence may identify
347 supportive cells near terminals from which neuropeptide release is NO dependent and terminals
348 adjacent to areas lacking NO-FL rely on another mechanism for peptide release.

349 As MIH transcript levels remain constant over the molt cycle, MIH synthesis and secretion
350 are regulated by post-transcriptional mechanisms [(Chung and Webster, 2003); N.L. Pitts and
351 D.L. Mykles, unpublished]. NO inhibits neuropeptide release in the hippocampus, bovine
352 chromaffin cells, basal forebrain, and nucleus accumbens in the mammalian brain (Sequeira et
353 al., 1997; Schwarz et al., 1998; Philippu and Prast, 2001). As NO is produced rapidly and
354 quickly diffuses across cell membranes, we propose that variations in NO release provide a
355 mechanism for regulating the pulsatile release of MIH. If NO inhibits MIH secretion from the
356 SG, then it follows that NO synthesis and release should vary with molt stage: it should be
357 highest during premolt and postmolt stages and lowest during intermolt. There is measurable

358 NO production in SG of intermolt animals, but other molt stages were not examined (Fig. 3, 4,
359 5). The amount of NO released is determined by NOS activity and/or NO sequestration. The
360 experiments with cPTIO and L-NAME showed that about 60% of the NO-FL fluorescence
361 during the loading period was from the release of NO from an endogenous storage protein (Figs.
362 4, 5). Sequestration of NO during intermolt would reduce NO release, resulting in elevated MIH
363 secretion from the SG. The higher frequency and amount of MIH release would keep the YO in
364 the basal state (Chung and Webster, 2003; Mykles et al., 2010; Chang and Mykles, 2011; Covi et
365 al., 2012). The hypothesis predicts that NO release increases during premolt, resulting from
366 increased NOS activity, decreased NO sequestration, or a combination of the two. Future work
367 will address this question by measuring total NO-FL fluorescence, as well as the contribution of
368 the NO storage protein to total NO-FL fluorescence, in the SG from intermolt, premolt, and
369 postmolt animals.

370 In summary, the SG is a site of higher NO production in the ESG of intermolt *C. maenas*.
371 As a highly specific and sensitive indicator of NO, CuFL is an effective probe for NO production
372 in living cells. CuFL readily penetrates tissues and reacts with NO to form NO-FL, making it a
373 more effective NO scavenger than cPTIO. NO-FL is highly fluorescent, requiring very low
374 concentrations (0.05 μM) of CuFL, which minimizes non-specific and possible toxic effects.
375 NO-FL is stable at neutral pH, which allows for the quantification and localization of NO over a
376 period of several hours. To our knowledge, this is the first report using CuFL to image and
377 measure NO in crustacean tissues. The effects of azide, cPTIO, and L-NAME on NO-FL
378 fluorescence indicate that greater than half of the NO synthesized by NOS was sequestered by an
379 endogenous storage protein. Azide-dependent spectral shift analysis of SG soluble extract
380 indicated that NO was bound to a metal-containing protein, but the metal is not iron or copper.
381 The localization of NOS and NO-FL to supportive tissues suggests that NO produced and
382 released by glial cells modulates neuropeptide secretion from axon terminals. The episodic
383 release of MIH may be regulated by a NO/cGMP-dependent feedback mechanism. NO
384 sequestration during intermolt may dampen the feedback mechanism, thus increasing MIH
385 pulses to maintain the YO in the basal state during intermolt (Mykles et al., 2010; Chang and
386 Mykles, 2011; Covi et al., 2012). Increased NO release due to increased NOS activity and/or
387 decreased NO sequestration enhances the negative feedback loop. Consequently, the reduction in

388 MIH pulses drives the transition of YO from the basal to activated state and the animal enters
389 premolt.

390

391 **Materials and Methods**

392 *Animals*

393 Green shore crabs were collected from Bodega Harbor in Bodega Bay, California. They
394 were maintained under ambient conditions in a flow-through sea water system (12-15 °C) at
395 Bodega Marine Laboratory (Abuhagr et al., 2014). Only intermolt (stage C₄) adult male crabs
396 were used. Molt stage was determined by hemolymph ecdysteroid concentrations and the
397 presence or absence of the membranous layer in the exoskeleton (Abuhagr et al., 2014).
398 Ecdysteroids were quantified using a competitive enzyme-linked immunoassay (Kingan, 1989;
399 Abuhagr et al., 2014).

400

401 *End-point PCR*

402 Tissue expression of *Cm-NOS* (GenBank accession #GQ862349) was determined using
403 end-point RT-PCR. *Cm-EF2* (GenBank accession #GU808334) is a constitutively expressed
404 gene and served as a control to assess the quality of RNA isolations and cDNA synthesis. RNA
405 was isolated from tissues of an intermolt male *C. maenas* using TRIzol reagent (Life
406 Technologies, Carlsbad, CA USA) according to the manufacture's protocol. Total RNA was
407 treated with DNase I (New England Biolabs, Ipswich, MA USA) followed by a
408 phenol:chloroform extraction. RNA was precipitated overnight in a 3:1 mixture of isoamyl
409 alcohol:sodium acetate (pH 5.2) and re-suspended in 20 µL nuclease free water. RNA was
410 reverse transcribed with Transcriptor Reverse Transcriptase (Roche Diagnostics, Indianapolis,
411 IN USA) and an oligo-dT primer (50 µmol). PCR reactions contained 1 µL template cDNA, 0.5
412 µL 10 µM forward primer (*Cm-NOS*, 5'-GTG TGG AAG AAG AAC AAG GAC C-3'; *Cm-EF2*,
413 5'-CCA TCA AGA GCT CCG ACA ATG AGC G-3'), 0.5 µL 10 µM reverse primer (*Cm-NOS*,
414 5'-TCT GTG GCA TAG AGG ATG GTG G-3'; *Cm-EF2*, 5'-CAT TTC GGC ACG GTA CTT
415 CTG AGC G-3'), 5 µL 2x PCR master mix (Thermo Scientific, Rockford, IL USA), and 3 µL
416 sterile deionized water. Primers were synthesized by Integrative DNA Technologies (Coralville,
417 IA USA). PCR conditions were as follows: 5 min denaturation at 95 °C, 35 cycles of 30 sec
418 denaturation at 95 °C, 30 sec annealing at 58 °C (*Cm-NOS*) or 61 °C (*Cm-EF2*), 30 sec extension

419 at 72 °C, and final extension at 72 °C for 7 min. Products were separated on a 1.5% agarose gel
420 and stained with ethidium bromide.

421

422 *Western Blot Analysis*

423 Twelve SG were homogenized in 150 µL buffer containing 20 mM Tris-HCl (pH 7.4), 1
424 mM EDTA, 20 mM KCl, and 10% protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO
425 USA) for 5 min and centrifuged at 30,000 g for 15 min. A sample of the supernatant fraction (24
426 µL; 50 µg protein) was combined with 8 µL sodium dodecyl sulfate-polyacrylamide gel
427 electrophoresis (SDS-PAGE) sample buffer (Bio-Rad Laboratories, Inc., Hercules, CA USA)
428 and incubated at 95 °C for 10 min. SG protein samples and SeeBlue Plus 2 pre-stained standard
429 (Invitrogen, Carlsbad, CA USA) were separated by SDS-PAGE (200V, 30 min) on a Mini-
430 Protean TGX 4-15% Tris-glycine gel (Bio-Rad Laboratories, Hercules, CA USA) using a Tris-
431 glycine buffer system. Proteins were transferred to a polyvinylidene difluoride (PVDF)
432 membrane (100 V, 1 h) and incubated in Tris-buffered saline + Tween-20 (TTBS) plus 2% goat
433 serum (Vector Laboratories, Inc., Burlingame, CA USA) for 45 min at room temperature (RT),
434 followed by an overnight incubation in a 1:100 dilution of the anti-universal NOS antibody
435 (PA1-38835; Pierce Antibodies, Thermo Scientific, Rockford, IL USA) or 2% goat serum
436 (control without primary antibody). The anti-universal NOS antibody recognized a highly
437 conserved peptide sequence (QKRYHEDIFG) in NOS proteins from various species, including
438 *C. maenas* (McDonald et al., 2011). Proteins were incubated with a goat anti-rabbit biotinylated
439 secondary antibody in TTBS for 1 h at RT, followed by 30 min at RT in Vectastain ABC reagent
440 (both from Vector Laboratories, Burlingame, CA USA). The membrane was developed with
441 WesternBright Sirius chemiluminescent HRP substrate (Advansta, Menlo Park, CA USA)
442 according to kit instructions. Images were obtained using a ChemiDoc XRS+ Molecular Imager
443 (Bio-Rad Laboratories, Hercules, CA USA). Band intensities from the Western Blot analysis
444 were measured with Image Lab software (Bio-Rad Laboratories, Hercules, CA, USA).

445

446 *Imaging and quantification of NO-FL fluorescence*

447 NO was imaged in live cells using Cu-FL, a cell-permeable Cu (II) fluorescein-based ligand,
448 which was made by combining CuCl₂ and FL (2-{2-chloro-6-hydroxy-5-[2-methylquinolin-8-
449 ylaminomethyl]-3-oxo3H-xanthen-9}); Strem Chemicals, Newburyport, MA USA) in a 1:1

450 molar ratio (Lim et al., 2006). ESG and SG were dissected in crab saline, preincubated with crab
451 saline or with 1 mM cPTIO (Cayman Chemical, Ann Arbor, MI, USA), and/or 1 mM L-NAME
452 (Cayman Chemical, Ann Arbor, MI, USA), and/or 1 mM NaN₃ in crab saline for 30 min in the
453 dark; and loaded for 1 h with 0.05 μM CuFL in crab saline with or without 1 mM cPTIO or 1
454 mM L-NAME in the dark. As SG size and fluorescence intensity varied between individuals, one
455 SG of a pair received the control treatment and the other SG received the experimental treatment.
456 The treatments are detailed in the Results. After CuFL loading, tissues were transferred to crab
457 saline and fluorescence intensity (arbitrary units) was quantified on an Olympus BX50WI
458 microscope (excitation 494 nm, emission 519 nm, exposure time 1 sec, 10x) using Metamorph
459 Image Analysis software (Molecular Devices LLC, Sunnyvale, CA USA). A SG was optically
460 divided into 4 quadrants and the average intensity of each image was summed to calculate the
461 total fluorescence intensity for the entire SG. After quantification, SG were imaged with an
462 Olympus Fluoroview FV 500 confocal laser scanning biological microscope (488 nm excitation,
463 519 nm emission, 10x objective). Images were composites of 20 stacked optical sections.
464 Quantification and imaging of SG pairs was completed less than 2 h after the end of the loading
465 period.

466 467 *Cell viability imaging*

468 A LIVE/DEAD Sperm Viability Kit (L-7011; Molecular Probes, Eugene, OR, USA) was
469 used to identify live and dead cells in isolated SG. SG were incubated 30 min in crab saline, 70%
470 methanol, or 1 mM NaN₃ in crab saline and stained 5 min with 12 μM propidium iodide in crab
471 saline followed by 10 μM Hoechst 33342 stain (H211492; Molecular Probes, Eugene, OR, USA)
472 in crab saline. SG were imaged with an Olympus Fluoroview FV 500 confocal laser scanning
473 biological microscope (358 nm excitation, 461 nm emission for Hoechst and excitation 494 nm,
474 emission 519 nm for PI with 20x objective) as described above. In false-color images, PI staining
475 was set as green and Hoechst staining was set as red. The ratio of dead to live cells was obtained
476 by counting the number of yellow/orange and red nuclei, respectively, for each treatment by 7
477 naïve observers. The observers were given the 3 unlabeled overlay images (Fig. 6), as well as a
478 legend showing examples of red, orange, and yellow nuclei. Observers were instructed to count
479 the number of red and yellow/orange cells in each image. The ratio of dead to live cells for each
480 observer was calculated and averaged.

481

482 *Spectral shift analysis*

483 Thirty SG were homogenized in 2 mL of phosphate buffered saline (137 mM NaCl; 10 mM
484 sodium phosphate, pH, 7.4; and 2.7 mM KCl). Homogenate samples (0.5 mL aliquotes) were
485 flash frozen in liquid nitrogen. On the day of the experiment, samples were thawed on ice and
486 centrifuged at 30,000 g for 15 min at 4°C to remove cellular debris. Samples were kept in the
487 dark whenever possible. Spectra at 1 nm intervals were recorded with 5 sec integration using an
488 Agilent 8453 diode array spectrophotometer (Agilent Technologies, Inc. Santa Clara, CA USA)
489 from 190 nm to 1100 nm and analyzed using UV-Visible Chemstation Version B.01.01 software
490 (Agilent Technologies, Inc. Santa Clara, CA USA). The cuvette path length was 1 cm and
491 spectra ranged from 0.5 to 1.0 absorbance units across the entire spectral range. Following a
492 baseline measurement, 10 μ L 1 M NaN₃ was added directly to the sample and a reading was
493 taken every 5 min for 1 h. Differences in spectra were calculated by subtracting each 5 min time
494 interval after the addition of azide from the baseline measurement before azide.

495

496 *Statistical analyses and software*

497 Statistical analysis used Sigma Plot 12.0 software (Systat Software Inc., San Jose CA,
498 USA). Differences in mean fluorescent intensities between control and experimental SG used a
499 paired t-test analysis. Differences in dead to live cell ratios between treatment groups and
500 observers used a Kruskal-Wallis analysis (variance on ranks). Data are presented as mean \pm 1 s.e.
501 and the level of significance was set at $\alpha = 0.05$. Graphs were constructed in Sigma Plot. All
502 other figures were created using Illustrator and Photoshop 10 (Adobe Systems, San Jose, CA,
503 USA).

504

505 **Symbols and Abbreviations**

506 cGMP: 3'5'-guanosine monophosphate

507 CHH: crustacean hyperglycemic hormone

508 CNS: central nervous system

509 cPTIO: 2-(4-Carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (NO scavenger)

510 CuFL: Cu(II) fluorescein based ligand

511 DAF-2: 4,5-diaminofluorescein-2

- 512 EF2: elongation factor 2
513 ESG: eyestalk ganglia
514 FL: 2-{2-chloro-6-hydroxy-5-[2-methylquinolin-8-ylaminomethyl]-3-oxo3H-xanthen-9};
515 fluorescent ligand
516 GC-I: soluble class I guanylyl cyclase
517 L-NAME: L-N^G-Nitroarginine methyl ester
518 MeOH: methanol
519 MI: medulla interna
520 MIH: molt inhibiting hormone
521 MT: medulla terminalis
522 NADPH: nicotinamide adenine dinucleotide phosphate
523 NaN₃: sodium azide
524 NO: nitric oxide
525 NO₂: nitrogen dioxide
526 NO₂O₃: dinitrogen trioxide
527 NO-FL: nitric oxide-fluorescent complex
528 NOS: nitric oxide synthase; eNOS = endothelial NOS, iNOS = inducible NOS, nNOS = neuronal
529 NOS
530 PG: prothoracic gland
531 PTTH: prothoracicotrophic hormone
532 PVDF: polyvinylidene difluoride
533 RT: room temperature
534 RT-PCR: reverse transcriptase polymerase chain reaction
535 SDS-PAGE: sulfate-polyacrylamide gel electrophoresis
536 SG: sinus gland
537 TTBS: tris-buffered saline + tween
538 XO: X-organ
539 YC-1: 5-[1-(phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol; NO independent activator of GC-
540 I
541 YO: Y-organ
542

543 **Acknowledgements**

544 We thank Dr. Ernest S. Chang, UC Davis Bodega Marine Laboratory, for manuscript comments
545 and providing laboratory facilities and equipment; Dr. Sukkrit Nimitkul, UC Davis Bodega
546 Marine Laboratory, for animal collection and care and technical assistance; Dr. Gary Cherr, UC
547 Davis Bodega Marine Laboratory, for assistance with the Fluorescence Imaging Facility; and Dr.
548 P. Shing Ho, Colorado State University, for providing equipment and facilities for the spectral
549 shift analysis and for comments on the manuscript.

550

551 **Funding**

552 This research was supported by a grant from the National Science Foundation to D.L.M. (IOS-
553 1257732) and by travel grants awarded to N.L.P. from The Crustacean Society, The Journal of
554 Experimental Biology Traveling Fellowship, and The Society for Integrative and Comparative
555 Biology Grants in Aid of Research.

556

557 **Author Contributions**

558 N.L.P and D.L.M. designed the study; N.L.P completed the experiments; and N.L.P. and D.L.M.
559 prepared the manuscript.

560

561 **Competing Interests**

562 The authors declare no competing financial interests.

563

564 **References**

- 565 **Abuhagr, A. M., Blindert, J. L., Nimitkul, S., Zander, I. A., LaBere, S. M., Chang, S. A.,**
566 **MacLea, K. S., Chang, E. S. and Mykles, D. L.** (2014). Molt regulation in green and red
567 color morphs of the crab *Carcinus maenas*: gene expression of molt-inhibiting hormone
568 signaling components. *J. Exp. Biol.* **217**, 796-808.
- 569 **Aonuma, H., Nagayama, T. and Takahata, M.** (2000). Modulatory effects of nitric oxide on
570 synaptic depression in the crayfish neuromuscular system. *J. Exp. Biol.* **203**, 3595-3602.
- 571 **Aonuma, H., Nagayama, T. and Takahata, M.** (2002). Nitric oxide and cyclic GMP modulate
572 synaptic transmission in the local circuits of the crayfish. In *The Crustacean Nervous*
573 *System*, (ed. K. Wiese), pp. 305-312. Berlin: Springer.
- 574 **Assumpcao, T. C. F., Francischetti, I. M. B., Andersen, J. F., Schwarz, A., Santana, J. M.**
575 **and Ribeiro, J. M. C.** (2008). An insight into the sialome of the blood-sucking bug
576 *Triatoma infestans*, a vector of Chagas' disease. *Insect Biochem. Molec. Biol.* **38**, 213-232.
- 577 **Azzouna, A. and Rezig, M.** (2001). Ultrastructural study of the sinus gland of the shrimp
578 *Palaemonetes mesogenitor* Sollaud, 1912. *B. Soc. Zool. Fr.* **126**, 217-219.
- 579 **Bishop, C. D. and Brandhorst, B. P.** (2001). The role of NO/cGMP and HSP90 in regulating
580 metamorphosis of the sea urchin *Lytechinus pictus*. *Dev. Biol.* **235**, 251-251.
- 581 **Bogdan, C.** (2001). Nitric oxide and the regulation of gene expression. *Trends Cell Biol.* **11**, 66-
582 75.
- 583 **Caceres, L., Necakov, A. S., Schwartz, C., Kimber, S., Roberts, I. J. H. and Krause, H. M.**
584 (2011). Nitric oxide coordinates metabolism, growth, and development via the nuclear
585 receptor E75. *Genes Dev.* **25**, 1476-1485.
- 586 **Calabrese, V., Mancuso, C., Calvani, M., Rizzarelli, E., Butterfield, D. A. and Stella, A. M.**
587 **G.** (2007). Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity.
588 *Nat. Rev. Neurosci.* **8**, 766-775.
- 589 **Carrico, I. S.** (2004). Protein Engineering Through *in vivo* Incorporation of Phenylalanine
590 Analogs. Doctor of Philosophy. Pasadena, CA: California Institute of Technology.
- 591 **Chang, E. S. and Mykles, D. L.** (2011). Regulation of crustacean molting: A review and our
592 perspectives. *Gen. Comp. Endocrinol.* **172**, 323-330.

- 593 **Chung, J. S. and Webster, S. G.** (2003). Moulting cycle-related changes in biological activity of
594 moulting-inhibiting hormone (MIH) and crustacean hyperglycaemic hormone (CHH) in the
595 crab, *Carcinus maenas* - From target to transcript. *Eur. J. Biochem.* **270**, 3280-3288.
- 596 **Colasanti, M. and Venturini, G.** (1998). Nitric oxide in invertebrates. *Molec. Neurobiol.* **17**,
597 157-174.
- 598 **Cooke, I. M.** (1985). Electrophysiological characterization of peptidergic neurosecretory
599 terminals. *J. Exp. Biol.* **118**, 1-35.
- 600 **Cooper, C. E.** (1999). Biochemistry of nitric oxide. *Biochim. Biophys. Acta* **1411**, 215-216.
- 601 **Covi, J. A., Chang, E. S. and Mykles, D. L.** (2012). Neuropeptide signaling mechanisms in
602 crustacean and insect molting glands. *Invert. Reprod. Dev.* **56**, 33-49.
- 603 **Fu, Q., Kutz, K. K., Schmidt, J. J., Hsu, Y. W. A., Messinger, D. I., Cain, S. D., De la**
604 **Iglesia, H. O., Christie, A. E. and Li, L. J.** (2005). Hormone complement of the *Cancer*
605 *productus* sinus gland and pericardial organ: An anatomical and mass spectrometric
606 investigation. *J. Comp. Neurol.* **493**, 607-626.
- 607 **Garthwaite, J.** (2008). Concepts of neural nitric oxide-mediated transmission. *Eur. J. Neurosci.*
608 **27**, 2783-2802.
- 609 **Gusarov, I., Gautier, L., Smolentseva, O., Shamovsky, I., Eremina, S., Mironov, A. and**
610 **Nudler, E.** (2013). Bacterial nitric oxide extends the lifespan of *C. elegans*. *Cell* **152**, 818-
611 830.
- 612 **Haseloff, R. F., Zollner, S., Kirilyuk, I. A., Grigorev, I. A., Reszka, R., Bernhardt, R.,**
613 **Mertsch, K., Roloff, B. and Blasig, I. E.** (1997). Superoxide-mediated reduction of the
614 nitroxide group can prevent detection of nitric oxide by nitronyl nitroxides. *Free Radical*
615 *Res.* **26**, 7-17.
- 616 **Hirst, D.G. and Robson T.** (2011). Nitric oxide physiology and pathology. *Methods in Molec.*
617 *Biol.* **704**, 1-13.
- 618 **Hopkins, P. M.** (2012). The eyes have it: A brief history of crustacean neuroendocrinology.
619 *Gen. Comp. Endocrinol.* **175**, 357-366.
- 620 **Hurst, W. J., Moroz, L. L., Gillette, M. U. and Gillette, R.** (1999). Nitric oxide synthase
621 immunolabeling in the molluscan CNS and peripheral tissues. *Biochem. Biophys. Res.*
622 *Commun.* **262**, 545-548.

- 623 **Inada, M., Mekata, T., Sudhakaran, R., Okugawa, S., Kono, T., El Asely, A. M., Linh, N. T.**
624 **H., Yoshida, T., Sakai, M., Yui, T. et al.** (2010). Molecular cloning and characterization of
625 the nitric oxide synthase gene from kuruma shrimp, *Marsupenaeus japonicus*. *Fish Shellfish*
626 *Immunol.* **28**, 701-711.
- 627 **Johansson, K. U. I. and Carlberg, M.** (1994). NADPH-diaphorase histochemistry and nitric
628 oxide synthase activity in deutocerebrum of the crayfish, *Pacifastacus leiusculus* (Crustacea,
629 Decapoda). *Brain Res.* **649**, 36-42.
- 630 **Kim, H. W., Batista, L. A., Hoppes, J. L., Lee, K. J. and Mykles, D. L.** (2004). A crustacean
631 nitric oxide synthase expressed in nerve ganglia, Y-organ, gill and gonad of the tropical land
632 crab, *Gecarcinus lateralis*. *J. Exp. Biol.* **207**, 2845-2857.
- 633 **Kingan, T. G.** (1989). A competitive enzyme-linked immunosorbent assay: application in the
634 assay of peptides, steroids, and cyclic nucleotides. *Anal. Biochem.* **183**, 283-289.
- 635 **Lachaise, F., Leroux, A., Hubert, M. and Lafont, R.** (1993). The molting gland of
636 crustaceans: localization, activity, and endocrine control (a review). *J. Crustacean Biol.* **13**,
637 198-234.
- 638 **Lee, C. Y., Zou, H. S., Yau, S. M., Ju, Y. R. and Liao, C. S.** (2000). Nitric oxide synthase
639 activity and immunoreactivity in the crayfish *Procambarus clarkii*. *Neuroreport* **11**, 1273-
640 1276.
- 641 **Li, S. K., Zhang, Z., Li, C. B., Zhou, L. Z., Liu, W. H., Li, Y. Y., Zhang, Y. L., Zheng, H. P.**
642 **and Wen, X. B.** (2012). Molecular cloning and expression profiles of nitric oxide synthase
643 (NOS) in mud crab *Scylla paramamosain*. *Fish Shellfish Immunol.* **32**, 945-946.
- 644 **Lim, M. H., Xu, D. and Lippard, S. J.** (2006). Visualization of nitric oxide in living cells by a
645 copper-based fluorescent probe. *Nat. Chem. Biol.* **2**, 375-380.
- 646 **Lorenc-Koci, E. and Czarnecka, A.** (2013). Role of nitric oxide in the regulation of motor
647 function. An overview of behavioral, biochemical and histological studies in animal models.
648 *Pharmacol. Rep.* **65**, 1043-1055.
- 649 **Mahadevan, A., Lappe, J., Rhyne, R. T., Cruz-Bermudez, N. D., Marder, E. and Goy, M. F.**
650 (2004). Nitric oxide inhibits the rate and strength of cardiac contractions in the lobster
651 *Homarus americanus* by acting on the cardiac ganglion. *J. Neurosci.* **24**, 2813-2824.

- 652 **Martin, K. D., Saari, L., Wang, G. X., Wang, T., Parkhurst, L. J. and Klucas, R. V.** (1990).
653 Kinetics and thermodynamics of oxygen, CO, and azide binding by the subcomponents of
654 soybean leghemoglobin. *J. Biol. Chem.* **265**, 19588-19593.
- 655 **Martinez, A., Riverosmoreno, V., Polak, J. M., Moncada, S. and Sesma, P.** (1994). Nitric
656 oxide (NO) synthase immunoreactivity in the starfish *Marthasterias glacialis*. *Cell Tiss.*
657 *Res.* **275**, 599-603.
- 658 **McDonald, A. A., Chang, E. S. and Mykles, D. L.** (2011). Cloning of a nitric oxide synthase
659 from green shore crab, *Carcinus maenas*: A comparative study of the effects of eyestalk
660 ablation on expression in the molting glands (Y-organs) of *C. maenas*, and blackback land
661 crab, *Gecarcinus lateralis*. *Comp. Biochem. Physiol.* **158A**, 150-162.
- 662 **McQuade, L. E., Ma, J., Lowe, G., Ghatpande, A., Gelperin, A. and Lippard, S. J.** (2010).
663 Visualization of nitric oxide production in the mouse main olfactory bulb by a cell-trappable
664 copper(II) fluorescent probe. *Proc. Natl. Acad. Sci. USA* **107**, 8525-8530.
- 665 **Miles, E. W. and Phillips, R. S.** (1985). Photoinactivation and photoaffinity labeling of
666 tryptophan synthase alpha-2 beta-2 complex by the product analog 6-azido-L-tryptophan.
667 *Biochem.* **24**, 4694-4703.
- 668 **Moncada, S., Palmer, R. M. J. and Higgs, E. A.** (1991). Nitric oxide; physiology,
669 pathophysiology, and pharmacology. *Pharmacol. Rev.* **43**, 109-142.
- 670 **Mungrue, I. N., Brecht, D. S., Stewart, D. J. and Husain, M.** (2003). From molecules to
671 mammals: what's NOS got to do with it? *Acta Physiol. Scand.* **179**, 123-135.
- 672 **Mykles, D. L., Adams, M. E., Gade, G., Lange, A. B., Marco, H. G. and Orchard, I.** (2010).
673 Neuropeptide action in insects and crustaceans. *Physiol. Biochem. Zool.* **83**, 836-846.
- 674 **Nathan, C. and Xie, Q. W.** (1994). Nitric oxide synthases: roles, tolls, and controls. *Cell* **78**,
675 915-918.
- 676 **Ott, S. R., Aonuma, H., Newland, P. L. and Elphick, M. R.** (2007). Nitric oxide synthase in
677 crayfish walking leg ganglia: Segmental differences in chemo-tactile centers argue against a
678 generic role in sensory integration. *J. Comp. Neurol.* **501**, 381-399.
- 679 **Palumbo, A.** (2005). Nitric oxide in marine invertebrates: A comparative perspective. *Comp.*
680 *Biochem. Physiol.* **142A**, 241-248.
- 681 **Philippu, A. and Prast, H.** (2001). Role of histaminergic and cholinergic transmission in
682 cognitive processes. *Drug News Perspect.* **14**, 523-529.

- 683 **Prast, H. and Philippu, A.** (1992). Nitric oxide releases acetylcholine in the basal forebrain.
684 *Eur. J. Pharmacol.* **216**, 139-140.
- 685 **Prast, H., Tran, M. H., Fischer, H. and Philippu, A.** (1998). Nitric oxide-induced release of
686 acetylcholine in the nucleus accumbens, role of cyclic GMP, glutamate, and GABA. *J.*
687 *Neurochem.* **71**, 266-273.
- 688 **Prast, H., Fischer, H., Werner, E., Wernerfeldmayer, G. and Philippu, A.** (1995). Nitric oxide
689 modulates the release of acetylcholine in the ventral striatum of the freely moving rat.
690 *Naunyn Schmiedebergs Arch. Pharmacol.* **352**, 67-73.
- 691 **Radomski, M. W., Martin, J. F. and Moncada, S.** (1991). Synthesis of nitric oxide by the
692 hemocytes of the American horseshoe crab (*Limulus polyphemus*) *Phil. Trans. R. Soc. Lond.*
693 *B.* **334**, 129-133.
- 694 **Regulski, M. and Tully, T.** (1995). Molecular and biochemical characterization of dNOS: a
695 *Drosophila* Ca²⁺/calmodulin-dependent nitric oxide synthase. *Proc. Natl. Acad. Sci. USA*
696 **92**, 9072-9076.
- 697 **Rewitz, K. F., Yamanaka, N. and O'Connor, M. B.** (2013). Developmental checkpoints and
698 feedback circuits time insect maturation. In *Animal Metamorphosis*, vol. 103 (ed. Y. B. Shi),
699 pp. 1-33.
- 700 **Ribeiro, J. M. C., Hazzard, J. M. H., Nussenzveig, R. H., Champagne, D. E. and Walker, F.**
701 **A.** (1993). Reversible binding of nitric oxide by a salivary heme protien from a
702 bloodsucking insect. *Science* **260**, 539-541.
- 703 **Roman, L. J., Martasek, P. and Masters, B. S. S.** (2002). Intrinsic and extrinsic modulation of
704 nitric oxide synthase activity. *Chem. Rev.* **102**, 1179-1189.
- 705 **Rudolph, P. H. and Spaziani, E.** (1991). Neurons demonstrable by nickel lysine backfilling of
706 the optic peduncle in the crab *Cancer antennarius*. *Comp. Biochem. Physiol.* **99C**, 179-184.
- 707 **Russwurm M., Russwurm C., Koesling D., Evanthia M.** (2013). NO/cGMP: The past, present,
708 and the future. *Methods in Molec. Biol.* **1020**, 1-16.
- 709 **Scholz, N. L.** (1999). NO/cGMP signaling and the specification of motor networks in the crab
710 stomatogastric ganglion. *Am. Zool.* **39**, 46A-46A.
- 711 **Scholz, N. L., Chang, E. S., Graubard, K. and Truman, J. W.** (1998). The NO/cGMP
712 pathway and the development of neural networks in postembryonic lobsters. *J. Neurobiol.*
713 **34**, 208-226.

- 714 **Scholz, N. L., Labenia, J. S., De Vente, J., Graubard, K. and Goy, M. F.** (2002). Expression
715 of nitric oxide synthase and nitric oxide-sensitive guanylate cyclase in the crustacean
716 cardiac ganglion. *J. Comp. Neurol.* **454**, 158-167.
- 717 **Schuppe, H., Cuttle, M., Chad, J. E. and Newland, P. L.** (2002). 4,5-Diaminofluoroscein
718 imaging of nitric oxide synthesis in crayfish terminal ganglia. *J. Neurobiol.* **53**, 361-369.
- 719 **Schwarz, P. M., Rodriguez-Pascual, F., Koesling, D., Torres, M. and Forstermann, U.**
720 (1998). Functional coupling of nitric oxide synthase and soluble guanylyl cyclase in
721 controlling catecholamine secretion from bovine chromaffin cells. *Neurosci.* **82**, 255-265.
- 722 **Sequeira, S. M., Ambrosio, A. F., Malva, J. O., Carvalho, A. P. and Carvalho, C. M.** (1997).
723 Modulation of glutamate release from rat hippocampal synaptosomes by nitric oxide. *Nitric*
724 *Oxide-Biol. Ch.* **1**, 315-329.
- 725 **Skinner, D. M.** (1985). Molting and regeneration. In *The Biology of Crustacea*, vol. 9 eds. D. E.
726 Bliss and L. H. Mantel), pp. 44-146. New York: Academic Press.
- 727 **Stasiv, Y., Regulski, M., Kuzin, B., Tully, T. and Enikolopov, G.** (2001). The *Drosophila*
728 nitric oxide synthase gene (dNOS) encodes a family of proteins that can modulate NOS
729 activity by acting as dominant negative regulators. *J. Biol. Chem.* **276**, 42241-42251.
- 730 **Stuenkel, E. L.** (1985). Simultaneous monitoring of electrical and secretory activity in
731 peptidergic neurosecretory terminals of the crab. *J. Physiol. Lond.* **359**, 163-187.
- 732 **Virarkar, M., Alappat, L., Bradford, P. G. and Awad, A. B.** (2013). L-arginine and nitric
733 oxide in CNS function and neurodegenerative diseases. *Crit. Rev. Food Sci. Nutr.* **53**, 1157-
734 1167.
- 735 **Vitecek, J., Reinohl, V. and Jones, R. L.** (2008). Measuring NO production by plant tissues and
736 suspension cultured cells. *Molec. Plant* **1**, 270-284.
- 737 **Weichsel, A., Maes, E. M., Andersen, J. F., Valenzuela, J. G., Shokhireva, T. K., Walker, F.**
738 **A. and Montfort, W. R.** (2005). Heme-assisted S-nitrosation of a proximal thiolate in a
739 nitric oxide transport protein. *Proc. Natl. Acad. Sci. USA* **102**, 594-599.
- 740 **Wilson, M. T. and Torres, J.** (2004). Reactions of nitric oxide with copper containing oxidases;
741 Cytochrome c oxidase and laccase. *Iubmb Life* **56**, 7-11.
- 742 **Wu, C. H., Siva, V. S. and Song, Y. L.** (2013). An evolutionarily ancient NO synthase (NOS) in
743 shrimp. *Fish Shellfish Immunol.* **35**, 1483-1500.

- 744 **Yao, C. L., Ji, P. F., Wang, Z. Y., Li, F. H. and Xiang, J. H.** (2010). Molecular cloning and
745 expression of NOS in shrimp, *Litopenaeus vannamei*. *Fish Shellfish Immunol.* **28**, 453-460.
- 746 **Yeh, F. C., Wu, S. H., Lai, C. Y. and Lee, C. Y.** (2006). Demonstration of nitric oxide synthase
747 activity in crustacean hemocytes and anti-microbial activity of hemocyte-derived nitric
748 oxide. *Comp. Biochem. Physiol.* **144B**, 11-17.
- 749 **Zou, H. S., Chang, Y. Z., Chen, S. C., Yau, S. M., Shen, Y. L. and Lee, C. Y.** (2002).
750 Localization of NADPH-diaphorase and nitric oxide synthase activity in the eyestalk of the
751 crayfish, *Procambarus clarkii*. *Zool. Stud.* **41**, 244-250.

752

753

754 **Figure Legends**

755

756 **Fig. 1. Tissue expression of *Cm-NOS* and *Cm-EF2* using end-point RT-PCR.** PCR products
 757 (158 bp for *Cm-NOS* and 278 bp for *Cm-EF2*) were separated on a 1.5% agarose gel and stained
 758 with ethidium bromide (inverted images). *Cm-EF2* was expressed in all tissues. *Cm-NOS* was
 759 expressed in all tissues except heart (Ht) and hepatopancreas (Hp). Other abbreviations: CM,
 760 claw muscle; TM, thoracic muscle; Gi, gill; Hg, hindgut; Mg, midgut; Br, brain; TG, thoracic
 761 ganglion; ESG, eyestalk ganglia; Te; testes; W, water (no template control).

762

763 **Fig. 2. Western blot analysis of *Cm-NOS* protein in the sinus gland.** SG soluble protein was
 764 separated by SDS-PAGE, transferred to PVDF membrane, and probed with (Lane a) or without
 765 (Lane b) universal NOS antibody. Detection of primary antibody used a goat anti-rabbit IgG plus
 766 ABC reagent and chemiluminescence (see Materials and Methods). The primary antibody
 767 recognized a protein of the predicted mass ~132-kDa for *Cm-NOS* and a second protein (~94
 768 kDa), which may represent an uncharacterized truncated NOS isoform. Protein standards, with
 769 approximate masses, are shown in the left panel.

770

771 **Fig. 3. Localization of NO-FL in the sinus gland *in situ*.** (A) Whole ESG was preincubated
 772 with crab saline for 30 min and loaded with 0.05 μ M CuFL for 1 h in the dark. Stacked images
 773 were obtained with a scanning laser confocal microscope at 10x magnification (scale bar = 200
 774 μ M). SG; sinus gland MI: medulla interna.

775

776 **Fig. 4. Effects of cPTIO and L-NAME on NO-FL fluorescence in the sinus gland during the**
 777 **preincubation period.** SGs were preincubated with saline, 1 mM cPTIO alone, or cPTIO in
 778 combination with 1 mM L-NAME for 30 min and loaded without or with 0.05 μ M CuFL for 1 h
 779 in the dark. (A) Total NO-FL fluorescence (mean \pm 1. s.e., n = 6). Gray-shaded columns compare
 780 relative fluorescence intensity between SG pairs preincubated in crab saline and loaded with or
 781 without CuFL. Open columns compare fluorescence between SG pairs preincubated with or
 782 without cPTIO and loaded with CuFL. Black-filled columns compare fluorescence between SG
 783 pairs preincubated with or without cPTIO and L-NAME. Significant differences, with p value,
 784 between SG pairs are indicated by horizontal lines. Numbers on the columns correspond to the
 785 confocal microscope images in (B). (B) Representative confocal images of SGs. Panels 1, 2, 3,

786 and 4 correspond to the column numbers in (A). All images were taken on a scanning laser
787 confocal microscope at 10x (scale bar = 200 μ M).

788

789 **Fig. 5. Effects of L-NAME, cPTIO, and NaN₃ on NO-FL fluorescence in the sinus gland.**

790 SGs were preincubated with saline or the indicated compound(s) for 30 min and loaded with 0.05
791 μ M CuFL plus the indicated compound(s). The concentration of cPTIO, L-NAME, and NaN₃
792 was 1 mM. (A) Total NO-FL fluorescence (mean \pm 1. s.e.). Light gray-shaded columns compare
793 fluorescence between SG pairs preincubated with saline and loaded with CuFL without or with
794 cPTIO (n = 9). Open columns compare fluorescence between SG pairs preincubated with cPTIO
795 and loaded with CuFL without or with cPTIO (n = 12). Black-filled columns compare
796 fluorescence between SG pairs preincubated with cPTIO and L-NAME and loaded with CuFL
797 without or with L-NAME (n = 10). Dark gray-shaded columns compare fluorescence between
798 SG pairs preincubated with cPTIO + L-NAME without or with NaN₃ and loaded with CuFL with
799 L-NAME (n = 6). Significant differences, with p value, between SG pairs are indicated by
800 horizontal lines. Numbers in the columns correspond to the confocal images in (B). (B)
801 Representative confocal images of SGs. Panels 1, 2, 3, and 4 correspond to the column numbers
802 in (A). All images were taken on a scanning laser confocal microscope at 10x (scale bar = 200
803 μ M).

804

805 **Fig. 6. Effects of sodium azide and 70% methanol on SG cell viability.** SG were incubated

806 with crab saline, 1 mM NaN₃, or 70% methanol for 30 min, stained with propidium iodide
807 (indicated with green) and Hoechst (indicated with red) stains, and imaged by confocal
808 microscopy (see Materials and Methods). The nuclei of glial and other supportive cells were
809 stained. Groups of axon termini were located in regions lacking nuclei (arrows). Dead cells were
810 identified by nuclei stained with both propidium and Hoechst (orange to yellow) in overlay
811 images. Scale bar = 100 μ M.

812

813 **Fig. 7. Effect of sodium azide on absorption spectra of soluble proteins from the sinus**

814 **gland.** Top panel shows the spectra of the SG extract prior to the addition of NaN₃ (red line – no
815 azide) and immediately after the addition of 1 mM NaN₃ (green line – 0 min). Bottom panel
816 shows spectral shifts at 5-min intervals after the addition of NaN₃. Spectra at 0 to 60 min are the

817 differences between the baseline spectrum (no azide) and the spectrum at a specific time point.
818 A positive spectral shift occurred at ~225 nm (black arrow) and a negative spectral shift occurred
819 at ~255 nm (white arrow).

820

821 **Fig. 8. Schematic diagram summarizing the effects of L-NAME, cPTIO, and NaN₃ on NO**
822 **production, sequestration, and degradation in the sinus gland.** NOS produces NO, which
823 binds NO-dependent proteins (not shown) or is sequestered by NO-binding protein (XX-NO).
824 NO scavenger cPTIO converts NO to NO₂. CuFL reacts with NO, reducing Cu (II) to Cu (I), to
825 produce highly fluorescent NO-FL. L-NAME decreases NO-FL fluorescence by inhibiting NOS.
826 cPTIO decreases NO-FL fluorescence during preincubation, but is out-competed by CuFL during
827 the loading period. Preincubation of SGs with NaN₃ displaces NO from the NO-binding protein
828 (N₃XX) and the NO combines with water to form nitrite and nitrate. Maximum reduction of NO-
829 FL fluorescence is achieved when the SG is preincubated with L-NAME, cPTIO, and NaN₃ and
830 when L-NAME is included during CuFL loading.

831

Answer:




Figure 2



Figure 1



Figure 4A



Preincubation Period	cPTIO	-	-	-	+	-	+
	L-NAME	-	-	-	-	-	+
Loading Period	CuFL	-	+	+	+	+	+


pre-ill

2003
2004

2005

2006

2007
2008
2009



2003

2004

2005

2006

Figure 5A




Figure 28





Figure 4






Figure 8

